In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General's High-Level Panel report on Access to Medicines and looks at the responsibilities it places on industry.
During the UN General Assembly in New York last month, the UN Secretary General’s High-Level Panel on Access to Medicines released its much-anticipated report, containing recommendations for governments and the pharmaceutical industry on how to enable better access to medicines and vaccines and how to ensure medical research and development (R&D) addresses unmet priority health needs.
As a medical humanitarian organization, we confront the effects of a lack of innovation for many diseases affecting patients on a daily basis, and we and our patients continually struggle to overcome barriers, like high prices, that prevent widespread access to needed medical tools.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze